| December 14, 2022 12:59 pm | — | Morgan Stanley | $60.00 | $43.73 | Benzinga |
Morgan Stanley Maintains Equal-Weight on Mirati Therapeutics, Lowers Price Target to $60 |
| December 14, 2022 4:00 am | — | Leerink Partners | $75.00 | $41.97 | Benzinga |
SVB Leerink Maintains Outperform on Mirati Therapeutics, Lowers Price Target to $75 |
| December 13, 2022 8:53 pm | Swapnil Malekar | Piper Sandler | $68.00 | $41.97 | TheFly |
Mirati Therapeutics price target lowered to $68 from $87 at Piper Sandler |
| December 13, 2022 6:25 am | — | Piper Sandler | $87.00 | $41.41 | Benzinga |
Piper Sandler Maintains Overweight on Mirati Therapeutics, Raises Price Target to $87 |
| December 9, 2022 8:50 am | — | Citigroup | $53.00 | $42.09 | Benzinga |
Citigroup Downgrades Mirati Therapeutics to Neutral, Lowers Price Target to $53 |
| December 8, 2022 8:53 am | — | Leerink Partners | $85.00 | $45.95 | Benzinga |
SVB Leerink Maintains Outperform on Mirati Therapeutics, Lowers Price Target to $85 |
| December 8, 2022 6:47 am | — | Oppenheimer | $60.00 | $49.59 | Benzinga |
Oppenheimer Maintains Perform on Mirati Therapeutics, Lowers Price Target to $60 |
| December 8, 2022 5:06 am | — | J.P. Morgan | $65.00 | $49.59 | Benzinga |
JP Morgan Downgrades Mirati Therapeutics to Neutral, Lowers Price Target to $65 |
| December 7, 2022 9:27 pm | Evan Seigerman | BMO Capital | $59.00 | $49.59 | TheFly |
Mirati Therapeutics downgraded to Market Perform from Outperform at BMO Capital |
| December 7, 2022 9:19 pm | Swapnil Malekar | Piper Sandler | $84.00 | $49.59 | TheFly |
Mirati Therapeutics price target lowered to $84 from $110 at Piper Sandler |
